Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for the treatment of bleeding and a variety of blood-related diseases. It offers SynthoPlate, a synthetic hemostatic agent that mitigates bleeding by acting at the site of injury and amplifying natural clotting mechanisms. The company focuses on platelet-inspired therapies to mitigate active bleeding and bleeding risks after traumatic injury, surgery, thrombocytopenia, and rare bleeding disorders.